One of biotech’s best-funded startups has just raised a huge new round to take its lead drug into final-stage testing.
On Wednesday, Eikon Therapeutics announced …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.